Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | SVP, IR & Corp. Affairs | December 31, 2021 | January 04, 2022 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | SVP, IR and Corp Comm | February 28, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date December 31, 2021 · Filed January 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,308 |
Reported balance
After 2021-12-31 transaction · row 1
1 source rowRow 1 · 2021-12-31 · Tax withholding · Disposed 542 · Balance 10,308 F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,869 |
Ending reported balance
After 2026-02-28 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-28 · Exercise / conversion · Acquired 24,674 · Balance 40,251 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-02-28 · Exercise / conversion · Acquired 128,190 · Balance 168,441 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 3 · 2026-02-28 · Tax withholding · Disposed 74,572 · Balance 93,869 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,673 |
Reported balance
After 2026-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-28 · Exercise / conversion · Disposed 24,674 · Balance 24,673 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F4: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 256,380 |
Reported balance
After 2026-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-28 · Exercise / conversion · Disposed 128,190 · Balance 256,380 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F4: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock.
F4: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2026 Filed Mar 3, 2026 12:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 128,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000037 · form4.xml · derivative · entry 5 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,380 Underlying: Common Stock · 128,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F4 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 24,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000037 · form4.xml · derivative · entry 4 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,673 Underlying: Common Stock · 24,674 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F4 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 74,572 | $1.47 | $109,620.84 |
DisclosureSEC source: 0001062822-26-000037 · form4.xml · nonDerivative · entry 3 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,869 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 128,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000037 · form4.xml · nonDerivative · entry 2 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 24,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000037 · form4.xml · nonDerivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:07 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 386,300 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001062822-26-000022 · form4.xml · derivative · entry 2 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,300 Underlying: Common Stock · 386,300 shares Expires 2036-02-12 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:07 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 257,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000022 · form4.xml · derivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,530 Underlying: Common Stock · 257,530 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 24,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007527 · form4.xml · derivative · entry 3 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,347 Underlying: Common Stock · 24,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F4 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 9,096 | $0.67 | $6,094.32 |
DisclosureSEC source: 0001127602-25-007527 · form4.xml · nonDerivative · entry 2 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,577 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 24,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007527 · form4.xml · nonDerivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 384,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-005218 · form4.xml · derivative · entry 2 DeFrancesco Lisa · CIK 0001846325 · VP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,570 Underlying: Common Stock · 384,570 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 576,850 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001127602-25-005218 · form4.xml · derivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · VP, IR and Corp Comm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,850 Underlying: Common Stock · 576,850 shares Expires 2035-02-13 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:18 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 542 | $16.29 | $8,829.18 |
DisclosureSEC source: 0001104659-22-000929 · tm221409d5_4.xml · nonDerivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR & Corp. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,308 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 17:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 204 | $14.85 | $3,029.40 |
DisclosureSEC source: 0001104659-21-122561 · tm2129223-2_4seq1.xml · nonDerivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR & Corp. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 538 | $15.05 | $8,096.90 |
DisclosureSEC source: 0001104659-21-113041 · tm2126933d1_4.xml · nonDerivative · entry 1 DeFrancesco Lisa · CIK 0001846325 · SVP, IR & Corp. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,054 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.